Category Archives: Muscular Dystrophy Treatment

Global Duchenne Muscular Dystrophy (DMD) Treatment Market Analysis, Size, Share, Outlook and Forecast to 2020-2027 is a professional and in-depth research report on the worlds major regional market conditions, focusing on the main regions (North America, Europe and Asia-Pacific). The market attractiveness analysis provided in the report aptly measures the potential value of the market providing business strategists with the latest growth opportunities. Continue reading →

The Duchenne Muscular Dystrophy (DMD) Treatment Market is expected to have a highly positive outlook over the forecast period 2020-2026 according to a Duchenne Muscular Dystrophy (DMD) Treatment Market research report. The Duchenne Muscular Dystrophy (DMD) Treatment report stresses the most recent advancements, development, new chances, and lethargic traps. It gives a comprehensive position of the Duchenne Muscular Dystrophy (DMD) Treatment Continue reading →

Rapid advances in artificial intelligence over the last decade have the potential to revolutionize how drugs are developed. Continue reading →

The Muscular Dystrophy Treatment Market report defines and briefs readers about its products, applications, and specifications. The research lists key companies operating in the market and also highlights the key changing course adopted by the companies to maintain their strength Continue reading →

Duchenne Muscular Dystrophy Treatment Market research is an intelligence report with meticulous efforts undertaken to study the right and valuable information. Continue reading →

Text size A question hanging over gene therapies, which attempt a once-and-done fix for genetic diseases, is will their benefits endure? Monday, Sarepta Therapeutics told a scientific conference that the first four children who got its investigational gene therapy, for Duchenne muscular dystrophy, all continued to show better-functioning muscles after two years Continue reading →

Gene therapy which aims to treat diseases by essentially inserting a gene into a patients cells rather than via drugs or surgery was a hot trend in the biotech space, but investor interest in the sector appears to have died down considerably, on account of high R&D spending and delays companies have seen in launching revenue-generating products.Our indicative theme of Gene-Based Therapy Stocks is down by about -23% year-to-date, underperforming the S&P 500 which is up by about 2%. However, with valuations declining, these companies could be attractive bets for investors as years of investments potentially start to pay off. Continue reading →

September 28, 2020 08:55 ET | Source: Sarepta Therapeutics, Inc. -- Continued functional improvements were observed at 18 months in the low-dose cohort -- -- First look at functional outcomes in high-dose cohort found improvements 6 months after administration -- -- Results in both cohorts continue to reinforce safety and tolerability profile of SRP-9003 -- CAMBRIDGE, Mass., Sept. Continue reading →

Sept. 28, 2020 12:00 UTC -- New Preclinical Research Indicates that Edasalonexent Could Have Positive Effects on Cardiac Function and Preserve Bone Health -- BOSTON--(BUSINESS WIRE)-- Catabasis Pharmaceuticals, Inc.. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today shared information on the edasalonexent program in Phase 3 development for Duchenne muscular dystrophy (DMD) in poster presentations at the Virtual 25th International Congress of the World Muscle Society Continue reading →

NEWPORT BEACH, Calif., Sept. Continue reading →